ICOS costimulation in combination with CTLA-4 blockade remodels tumor-associated macrophages toward an antitumor phenotype
(1) Sharma N (2) Fan X (3) Atolagbe OT (4) Ge Z (5) Dao KN (6) Sharma P (7) Allison JP
Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3_anti-GD2 bispecific antibody armed T cells
(1) Yankelevich M (2) Thakur A (3) Modak S (4) Chu R (5) Taub J (6) Martin A (7) Schalk D (8) Schienshang A (9) Whitaker S (10) Rea K (11) Lee DW (12) Liu Q (13) Shields AF (14) Cheung NV (15) Lum LG
(1) Yankelevich M (2) Thakur A (3) Modak S (4) Chu R (5) Taub J (6) Martin A (7) Schalk D (8) Schienshang A (9) Whitaker S (10) Rea K (11) Lee DW (12) Liu Q (13) Shields AF (14) Cheung NV (15) Lum LG
Author Info: (1) St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, USA yankelevic@gmail.com LGL4F@uvahealth.org. Children's Hospital of Michigan, Detroit, Michigan, USA. (2)
Author Info: (1) St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, USA yankelevic@gmail.com LGL4F@uvahealth.org. Children's Hospital of Michigan, Detroit, Michigan, USA. (2) University of Virginia Cancer Center, Charlottesville, Virginia, USA. (3) Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA. (4) Children's Hospital of Michigan, Detroit, Michigan, USA. (5) Children's Hospital of Michigan, Detroit, Michigan, USA. (6) Children's Hospital of Michigan, Detroit, Michigan, USA. (7) University of Virginia Cancer Center, Charlottesville, Virginia, USA. (8) University of Virginia Cancer Center, Charlottesville, Virginia, USA. (9) University of Virginia Cancer Center, Charlottesville, Virginia, USA. (10) University of Virginia Cancer Center, Charlottesville, Virginia, USA. (11) University of Virginia Cancer Center, Charlottesville, Virginia, USA. (12) Wistar Institute, Philadelphia, Pennsylvania, USA. (13) Karmanos Cancer Institute, Detroit, Michigan, USA. (14) Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA. (15) University of Virginia Cancer Center, Charlottesville, Virginia, USA yankelevic@gmail.com LGL4F@uvahealth.org.
Citation: J Immunother Cancer 2024 Mar 21 12: Epub03/21/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38519053
CD155 as an emerging target in tumor immunotherapy
(1) Wu JW (2) Liu Y (3) Dai XJ (4) Liu HM (5) Zheng YC (6) Liu HM
(1) Wu JW (2) Liu Y (3) Dai XJ (4) Liu HM (5) Zheng YC (6) Liu HM
Author Info: (1) State Key Laboratory of Esophageal Cancer Prevention & Treatment, Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education of China, Key Laboratory of He
Author Info: (1) State Key Laboratory of Esophageal Cancer Prevention & Treatment, Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education of China, Key Laboratory of Henan Province for Drug Quality and Evaluation, XNA Platform, School of Pharmaceutical Sciences, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, Henan 450001, China. (2) Henan Engineering Research Center for Application & Translation of Precision Clinical Pharmacy, Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, 1 Jianshe East Road, Zhengzhou 450052, China. (3) State Key Laboratory of Esophageal Cancer Prevention & Treatment, Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education of China, Key Laboratory of Henan Province for Drug Quality and Evaluation, XNA Platform, School of Pharmaceutical Sciences, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, Henan 450001, China. (4) State Key Laboratory of Esophageal Cancer Prevention & Treatment, Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education of China, Key Laboratory of Henan Province for Drug Quality and Evaluation, XNA Platform, School of Pharmaceutical Sciences, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, Henan 450001, China. (5) State Key Laboratory of Esophageal Cancer Prevention & Treatment, Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education of China, Key Laboratory of Henan Province for Drug Quality and Evaluation, XNA Platform, School of Pharmaceutical Sciences, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, Henan 450001, China. Electronic address: yichaozheng@zzu.edu.cn. (6) State Key Laboratory of Esophageal Cancer Prevention & Treatment, Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education of China, Key Laboratory of Henan Province for Drug Quality and Evaluation, XNA Platform, School of Pharmaceutical Sciences, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, Henan 450001, China. Electronic address: liuhuimin@zzu.edu.cn.
Citation: Int Immunopharmacol 2024 Mar 21 131:111896 Epub03/21/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38518596
The role of extracellular vesicle immune checkpoints in cancer
(1) Zhang W (2) Ou M (3) Yang P (4) Ning M
(1) Zhang W (2) Ou M (3) Yang P (4) Ning M
Author Info: (1) Department of Laboratory Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China. (2) Department of Laborat
Author Info: (1) Department of Laboratory Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China. (2) Department of Laboratory Medicine, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing Jiangsu, China. (3) Department of Laboratory Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China. (4) Department of Laboratory Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
Citation: Clin Exp Immunol 2024 Mar 22 Epub03/22/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38518192
Targeting pediatric cancers via T-cell recognition of the monomorphic MHC class I-related protein MR1
(1) Cornel AM (2) van der Sman L (3) van Dinter JT (4) Arrabito M (5) Dunnebach E (6) van Hoesel M (7) Kluiver TA (8) Lopes AP (9) Dautzenberg NMM (10) Dekker L (11) van Rijn JM (12) van den Beemt DAMH (13) Buhl JL (14) du Chatinier A (15) Barneh F (16) Lu Y (17) Lo Nigro L (18) Krippner-Heidenreich A (19) Sebestyn Z (20) Kuball J (21) Hulleman E (22) Drost J (23) van Heesch S (24) Heidenreich OT (25) Peng WC (26) Nierkens S
(1) Cornel AM (2) van der Sman L (3) van Dinter JT (4) Arrabito M (5) Dunnebach E (6) van Hoesel M (7) Kluiver TA (8) Lopes AP (9) Dautzenberg NMM (10) Dekker L (11) van Rijn JM (12) van den Beemt DAMH (13) Buhl JL (14) du Chatinier A (15) Barneh F (16) Lu Y (17) Lo Nigro L (18) Krippner-Heidenreich A (19) Sebestyn Z (20) Kuball J (21) Hulleman E (22) Drost J (23) van Heesch S (24) Heidenreich OT (25) Peng WC (26) Nierkens S
Author Info: (1) Prinses Maxima Centrum voor Kinderoncologie, Utrecht, The Netherlands. Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (2) Prinses Maxima Centrum vo
Author Info: (1) Prinses Maxima Centrum voor Kinderoncologie, Utrecht, The Netherlands. Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (2) Prinses Maxima Centrum voor Kinderoncologie, Utrecht, The Netherlands. Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (3) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (4) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. Center of Pediatric Hematology & Oncology, University of Catania, Catania, Italy. (5) Prinses Maxima Centrum voor Kinderoncologie, Utrecht, The Netherlands. Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (6) Prinses Maxima Centrum voor Kinderoncologie, Utrecht, The Netherlands. (7) Prinses Maxima Centrum voor Kinderoncologie, Utrecht, The Netherlands. (8) Prinses Maxima Centrum voor Kinderoncologie, Utrecht, The Netherlands. (9) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (10) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (11) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (12) Prinses Maxima Centrum voor Kinderoncologie, Utrecht, The Netherlands. (13) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. Oncode Institute, Utrecht, The Netherlands. (14) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (15) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (16) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (17) Center of Pediatric Hematology & Oncology, University of Catania, Catania, Italy. (18) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (19) Prinses Maxima Centrum voor Kinderoncologie, Utrecht, The Netherlands. (20) Prinses Maxima Centrum voor Kinderoncologie, Utrecht, The Netherlands. Department of Hematology, UMC Utrecht, Utrecht, The Netherlands. (21) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (22) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. Oncode Institute, Utrecht, The Netherlands. (23) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (24) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (25) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (26) Prinses Maxima Centrum voor Kinderoncologie, Utrecht, The Netherlands S.Nierkens-2@prinsesmaximacentrum.nl. Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands.
Citation: J Immunother Cancer 2024 Mar 21 12: Epub03/21/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38519054
CXCL9/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer
(1) Lim RJ (2) Salehi-Rad R (3) Tran LM (4) Oh MS (5) Dumitras C (6) Crosson WP (7) Li R (8) Patel TS (9) Man S (10) Yean CE (11) Abascal J (12) Huang Z (13) Ong SL (14) Krysan K (15) Dubinett SM (16) Liu B
(1) Lim RJ (2) Salehi-Rad R (3) Tran LM (4) Oh MS (5) Dumitras C (6) Crosson WP (7) Li R (8) Patel TS (9) Man S (10) Yean CE (11) Abascal J (12) Huang Z (13) Ong SL (14) Krysan K (15) Dubinett SM (16) Liu B
Author Info: (1) Division of Pulmonary and Critical Care, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA 90095, USA; Departmen
Author Info: (1) Division of Pulmonary and Critical Care, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA 90095, USA. (2) Division of Pulmonary and Critical Care, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Medicine, VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA. (3) Division of Pulmonary and Critical Care, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Medicine, VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA. (4) Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA 90095, USA; Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA. (5) Division of Pulmonary and Critical Care, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA 90095, USA. (6) Division of Pulmonary and Critical Care, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA 90095, USA. (7) Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA 90095, USA. (8) Division of Pulmonary and Critical Care, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA 90095, USA. (9) Division of Pulmonary and Critical Care, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA 90095, USA. (10) Division of Pulmonary and Critical Care, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA 90095, USA. (11) Division of Pulmonary and Critical Care, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA 90095, USA; Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA. (12) Division of Pulmonary and Critical Care, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA 90095, USA. (13) Division of Pulmonary and Critical Care, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA 90095, USA. (14) Division of Pulmonary and Critical Care, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Medicine, VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA. (15) Division of Pulmonary and Critical Care, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Medicine, VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA 90095, USA. Electronic address: sdubinett@mednet.ucla.edu. (16) Division of Pulmonary and Critical Care, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA 90095, USA. Electronic address: bliu@mednet.ucla.edu.
Citation: Cell Rep Med 2024 Mar 19 101479 Epub03/19/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38518770
Engineered extracellular vesicles enable high-efficient delivery of intracellular therapeutic proteins
(1) Ma D (2) Xie A (3) Lv J (4) Min X (5) Zhang X (6) Zhou Q (7) Gao D (8) Wang E (9) Gao L (10) Cheng L (11) Liu S
(1) Ma D (2) Xie A (3) Lv J (4) Min X (5) Zhang X (6) Zhou Q (7) Gao D (8) Wang E (9) Gao L (10) Cheng L (11) Liu S
Author Info: (1) Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China. Blo
Author Info: (1) Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China. Blood and Cell Therapy Institute, Anhui Provincial Key Laboratory of Blood Research and Applications, University of Science and Technology of China, Hefei 230036, China. School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China. (2) Blood and Cell Therapy Institute, Anhui Provincial Key Laboratory of Blood Research and Applications, University of Science and Technology of China, Hefei 230036, China. School of Biomedical Engineering, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230026, China. (3) School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China. (4) School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China. (5) School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China. (6) School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China. (7) School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China. (8) Blood and Cell Therapy Institute, Anhui Provincial Key Laboratory of Blood Research and Applications, University of Science and Technology of China, Hefei 230036, China. (9) Blood and Cell Therapy Institute, Anhui Provincial Key Laboratory of Blood Research and Applications, University of Science and Technology of China, Hefei 230036, China. (10) Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China. Blood and Cell Therapy Institute, Anhui Provincial Key Laboratory of Blood Research and Applications, University of Science and Technology of China, Hefei 230036, China. School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China. School of Biomedical Engineering, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230026, China. (11) Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China. Blood and Cell Therapy Institute, Anhui Provincial Key Laboratory of Blood Research and Applications, University of Science and Technology of China, Hefei 230036, China. School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China.
Citation: Protein Cell 2024 Mar 22 Epub03/22/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38518087
Tags:
An IRF2-Expressing Oncolytic Virus Changes the Susceptibility of Tumor Cells to Antitumor T cells and Promotes Tumor Clearance
(1) Shao L (2) Srivastava R (3) Delgoffe GM (4) Thorne SH (5) Sarkar SN
(1) Shao L (2) Srivastava R (3) Delgoffe GM (4) Thorne SH (5) Sarkar SN
Author Info: (1) University of Pittsburgh, Pittsburgh, PA, United States. (2) University of Pittsburgh, Pittsburgh, PA, United States. (3) University of Pittsburgh, Pittsburgh, PA, United State
Author Info: (1) University of Pittsburgh, Pittsburgh, PA, United States. (2) University of Pittsburgh, Pittsburgh, PA, United States. (3) University of Pittsburgh, Pittsburgh, PA, United States. (4) University of Pittsburgh, Pittsburgh, PA, United States. (5) University of Pittsburgh, Pittsburgh, PA, United States.
Citation: Cancer Immunol Res 2024 Mar 22 Epub03/22/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38517470
Melanoma extracellular vesicles inhibit tumor growth and metastasis by stimulating CD8 T cells
(1) Dan Y (2) Ma J (3) Long Y (4) Jiang Y (5) Fang L (6) Bai J
(1) Dan Y (2) Ma J (3) Long Y (4) Jiang Y (5) Fang L (6) Bai J
Author Info: (1) State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing 400016, China; Chongqing Key Laborato
Author Info: (1) State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing 400016, China; Chongqing Key Laboratory of Biomedical Engineering, Chongqing Medical University, Chongqing 400016, China. (2) State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing 400016, China; Chongqing Key Laboratory of Biomedical Engineering, Chongqing Medical University, Chongqing 400016, China. (3) State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing 400016, China; Chongqing Key Laboratory of Biomedical Engineering, Chongqing Medical University, Chongqing 400016, China. (4) State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing 400016, China; Chongqing Key Laboratory of Biomedical Engineering, Chongqing Medical University, Chongqing 400016, China. (5) State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing 400016, China; National Engineering Research Center of Ultrasound Medicine, Chongqing 401121, China. Electronic address: lqfang06@163.com. (6) State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing 400016, China; Chongqing Key Laboratory of Biomedical Engineering, Chongqing Medical University, Chongqing 400016, China. Electronic address: sajinbai@cqmu.edu.cn.
Citation: Mol Immunol 2024 Mar 20 169:78-85 Epub03/20/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38513590
cGAS-STING pathway mediates activation of dendritic cell sensing of immunogenic tumors
(1) Li G (2) Zhao X (3) Zheng Z (4) Zhang H (5) Wu Y (6) Shen Y (7) Chen Q
(1) Li G (2) Zhao X (3) Zheng Z (4) Zhang H (5) Wu Y (6) Shen Y (7) Chen Q
Author Info: (1) Fujian Key Laboratory of Innate Immune Biology, Biomedical Research Center of South China, College of Life Science, Fujian Normal University, Fuzhou, China. (2) Fujian Key Labo
Author Info: (1) Fujian Key Laboratory of Innate Immune Biology, Biomedical Research Center of South China, College of Life Science, Fujian Normal University, Fuzhou, China. (2) Fujian Key Laboratory of Innate Immune Biology, Biomedical Research Center of South China, College of Life Science, Fujian Normal University, Fuzhou, China. (3) Fujian Key Laboratory of Innate Immune Biology, Biomedical Research Center of South China, College of Life Science, Fujian Normal University, Fuzhou, China. (4) Fujian Key Laboratory of Innate Immune Biology, Biomedical Research Center of South China, College of Life Science, Fujian Normal University, Fuzhou, China. (5) Fujian Key Laboratory of Innate Immune Biology, Biomedical Research Center of South China, College of Life Science, Fujian Normal University, Fuzhou, China. (6) Fujian Key Laboratory of Innate Immune Biology, Biomedical Research Center of South China, College of Life Science, Fujian Normal University, Fuzhou, China. shenyk@fjnu.edu.cn. (7) Fujian Key Laboratory of Innate Immune Biology, Biomedical Research Center of South China, College of Life Science, Fujian Normal University, Fuzhou, China. chenqi@fjnu.edu.cn.
Citation: Cell Mol Life Sci 2024 Mar 21 81:149 Epub03/21/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38512518